SCHEMBL6489189

SCHEMBL6489189

Cc1cccc(C)c1C(=O)n1c(C)cc2cc(NC(=O)C3CC3)ccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.46
POLB P06746 1/20 0.45
LMNA P02545 2/20 0.44
UBE2M P61081 1/20 0.44
DCUN1D1 Q96GG9 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
ALDH1A1 P00352 1/20 0.44
GNRHR P30968 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
MAPT P10636 1/20 0.43
KMT2A Q03164 2/20 0.42
USP2 O75604 2/20 0.41
EPHX2 P34913 1/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
F2 P00734 1/20 0.41
ELANE P08246 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6490780 0.96 NPSR1 (0.48) HSD17B10POLBLMNAUBE2MDCUN1D1
SCHEMBL6480181 0.96 NPSR1 (0.51) HSD17B10POLBLMNAUBE2MDCUN1D1
SCHEMBL6480935 0.95 NPSR1 (0.50) HSD17B10LMNANPSR1ALDH1A1NPC1
SCHEMBL6487994 0.90 MEN1 (0.46) LMNAUBE2MDCUN1D1NPSR1GNRHR
SCHEMBL6489116 0.89 HSD17B10 (0.44) HSD17B10LMNANPSR1GNRHRMAPT
SCHEMBL6492249 0.89 PARP1 (0.48) HSD17B10POLBLMNAUBE2MDCUN1D1
SCHEMBL6480576 0.87 MTNR1A (0.47) POLBNPSR1ALDH1A1GNRHRMAPT
SCHEMBL6480891 0.86 NPSR1 (0.50) LMNAUBE2MDCUN1D1NPSR1ALDH1A1
SCHEMBL6492262 0.86 NPSR1 (0.47) POLBUBE2MDCUN1D1NPSR1ALDH1A1
SCHEMBL6490688 0.85 MGLL (0.44) HSD17B10POLBLMNAUBE2MDCUN1D1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050215614-A1 Substituted indoles and their use as hcv inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215614-A1 Substituted indoles and their use as hcv inhibitors IDO1, IDO2, HAVCR2 HSD17B10 980/4885POLB 4303/4885LMNA 4647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.